Lipid News

A new hotspot
for cyclooxygenase inhibition

Michael Malkowski
By Michael Malkowski
Jan. 21, 2020

Prostaglandins, or PGs, are critical players in such physiological housekeeping functions as the regulation of renal water and sodium metabolism, blood clotting, parturition, and stomach acid secretion. These potent lipid signaling molecules are derived from the oxygenation of arachidonic acid by prostaglandin endoperoxide H synthases 1 and 2, commonly called cyclooxygenase-1 and -2, or COX-1 and COX-2.

Abnormal changes in PG production contribute to disease pathologies including inflammation and cancer, so researchers view COX-1 and COX-2 as pharmacological targets. Indeed, nonselective nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen, inhibit both isoforms, while coxibs such as Celebrex selectively inhibit COX-2.

feb-lipid-news-Primary-900x506-1.jpg
Michael Malkowski
Cyclooxygenase structure. Each COX monomer comprises three domains and is bound by heme (red). Arachidonic acid (yellow) binds within the cyclooxygenase active site in an L-shaped conformation. The side chain of Leu-531 rotates from a closed conformation (blue) to an open conformation (gold) and in conjunction with Arg-513, located at the base of the side pocket, serves as a critical determinant for the inhibition of COX-2 by aspirin and Celebrex.

COX enzymes are sequence homodimers; each subunit consists of physically distinct cyclooxygenase and peroxidase active sites linked by a bridging heme moiety. In solution, the enzymes function as heterodimers, such that only one subunit is catalytically active at a time.

Structurally, COX-1 and COX-2 are virtually identical. However, subtle differences drive isoform-specific substrate specificity and inhibition. Among these are the substitutions of cyclooxygenase channel residues Ile-434, His-513 and Ile-523 in COX-1 for Val-434, Arg-513 and Val-523 in COX-2, which result in the formation of a unique side pocket and increased volume of the cyclooxygenase active site in COX-2. This side pocket, with Arg-513 at its base, has been exploited in the design of coxibs aimed at reducing the gastrointestinal side effects caused by conventional NSAIDs.

Many researchers focus on time-dependent inhibition of COX-2, working to identify the conformational changes that drive the transitions between the kinetically observable inhibitor binding states. These studies originally focused on the COX-2 side pocket, but recent molecular dynamics simulations identified a different region of the active site critical for aspirin and Celebrex to inhibit COX-2. These simulations identified rotation of the side chain of the residue Leu-531, opposite the side pocket, as a way to expand further the volume of the cyclooxygenase channel. Indeed, crystal structures of COX-2 have provided evidence for the existence of alternate rotamer conformations for this side chain when different ligands are bound.

To evaluate the importance of the conformational flexibility of the side chain of Leu-531, our research group generated L531F and L531N mutations and showed that these substitutions reduced aspirin and Celebrex’s inhibition of COX-2. Thus, expansion of the active site volume via the flexibility associated with the side chain of Leu-531 allows Celebrex to achieve a high-affinity binding state and facilitates formation of the initial noncovalent complex in the case of aspirin acetylation.

Deciphering the protein conformational motions associated with COX catalysis and inhibition is the next major frontier in studying this enzyme. If we understand how the binding of substrates, allosteric activators and inhibitors induce conformational motions to modulate COX activity, we will be closer to developing and repurposing drugs for maximum efficacy with minimal risks.

Michael Malkowski
Michael Malkowski

Michael G. Malkowski is a professor and chair of the department of structural biology in the Jacobs School of Medicine and Biomedical Sciences at the State University of New York at Buffalo.
 

Related articles

Ceramides’ role in liver disease
Eleonora Scorletti & Rotonya M. Carr
Share your aha moments!
Allison Frick
Winners of the ‘aha moments’ essay contest
Richard F. Ludueña, Mindy Engevik & Kazuhiko Igarashi
ASBMB welcomes new members
ASBMB Today Staff

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Ceramides’ role in liver disease
Lipid News

Ceramides’ role in liver disease

May 5, 2021

These biologically active sphingolipids have roles in apoptosis, inflammation and insulin resistance, all critical factors in the pathogenesis of chronic liver disease.

Winners of the ‘aha moments’ essay contest
Contest

Winners of the ‘aha moments’ essay contest

May 4, 2021

To celebrate our three journals going open access, we invited readers to share their moments of discovery in science. Here are the first, second and third place winners.

The 17th-century cloth merchant who discovered the vast realm of tiny microbes
News

The 17th-century cloth merchant who discovered the vast realm of tiny microbes

May 2, 2021

Although untrained in science, Antonie van Leeuwenhoek became the greatest lens-maker of his day, discovered microscopic life forms and is known today as the “father of microbiology.”

Do kids really need to be vaccinated for COVID?
News

Do kids really need to be vaccinated for COVID?

May 1, 2021

Many experts argue that Covid-19 cannot be curbed without vaccinating children. But others aren’t so sure.

Targeting nitrated proteins could lead to new cancer drugs
Annual Meeting

Targeting nitrated proteins could lead to new cancer drugs

April 30, 2021

Researchers are studying these proteins’ potential as markers that could make tumor cells easy targets for new therapies.

Gene changes and long-haul COVID
Annual Meeting

Gene changes and long-haul COVID

April 30, 2021

Airway cells exposed to SARS-CoV-2 spike protein exhibited persisting changes in gene expression.